Head-To-Head Survey: Adaptimmune Therapeutics (NASDAQ:ADAP) & ProKidney (NASDAQ:PROK)

ProKidney (NASDAQ:PROK) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Profitability

This table compares ProKidney and Adaptimmune Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	N/A	N/A	-10.24%
Adaptimmune Therapeutics	-25.43%	-74.15%	-15.09%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ProKidney and Adaptimmune Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	0	3	2	0	2.40
Adaptimmune Therapeutics	0	0	4	0	3.00

ProKidney currently has a consensus price target of $4.50, suggesting a potential upside of 258.57%. Adaptimmune Therapeutics has a consensus price target of $2.79, suggesting a potential upside of 405.81%. Given Adaptimmune Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than ProKidney.

Insider and Institutional Ownership

51.6% of ProKidney shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 41.5% of ProKidney shares are held by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

ProKidney has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.42, suggesting that its share price is 142% more volatile than the S&P 500.

Valuation and Earnings

This table compares ProKidney and Adaptimmune Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	N/A	N/A	-$35.47 million	($0.55)	-2.28
Adaptimmune Therapeutics	$60.28 million	2.34	-$113.87 million	($0.22)	-2.51

ProKidney has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Summary

ProKidney beats Adaptimmune Therapeutics on 7 of the 13 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.